Latest Us Growth News

Zip Co Limited reported a robust FY25 with revenue up 23.5% to $1.07 billion and cash earnings soaring 147%, driven by strong US market expansion and operational efficiencies.

QuickFee Limited reports a robust 25% revenue increase in FY25 alongside a return to profitability, setting a confident earnings guidance for FY26 backed by its expanding Connect platform.

ReNerve Limited has achieved a key milestone with its first sale and clinical use of a deep dermal tissue product in the US, broadening its surgical applications beyond nerve repair. This move complements its existing nerve repair portfolio and sets the stage for further product launches later this year.

The Calmer Co. has secured a long-term lease for its Navua facility in Fiji, replacing a planned property purchase and freeing up capital to accelerate its US market expansion.

xReality Group’s US subsidiary Operator XR has landed its largest order yet, a $5.7 million contract to supply VR training systems to the Texas Department of Public Safety, marking a significant milestone in its US expansion.

HeraMED advances AI-driven maternity care partnerships and strengthens its US commercial team, navigating policy uncertainties while progressing its global expansion and funding strategies.

AML3D has successfully commissioned its ARCEMY X system at the Tennessee Valley Authority, marking a significant milestone in its US expansion beyond defence into the energy sector.

Airtasker Limited has reported its second consecutive year of positive free cash flow alongside robust revenue growth, fueling accelerated expansion in the UK and US marketplaces.

Acrux Limited reports promising revenue growth driven by new topical generic launches in the US and secures crucial RDTI funding, marking a strategic shift under new CEO John Warmbrunn.

BetMakers Technology Group delivered a standout Q4 FY25 with record adjusted EBITDA and improved margins, while announcing a strategic acquisition to deepen its US market presence.

Nova Eye Medical has reported a record A$28.8 million in revenues for FY25, driven by strong US sales and sustained growth of its flagship iTrack™ Advance device.

Cochlear Limited has secured FDA approval for its latest Nucleus Nexa System and Kanso 3 sound processors, setting the stage for a US market debut in early FY26.